Lamotrigine in mood disorders

References

• Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol 1997;12(Suppl. 1):S10–S15
   PubMedGoogle Scholar
• Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharmaceutical Med 1991;1:121–8
   Google Scholar
• Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder [Review]. Neuropsychobiology 1998;38:119–30
   PubMed Web of Science ®Google Scholar
• Hassel B, Tauboll E, Gjerstad L. Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels. Epilepsy Res 2001;43:153–63
   Google Scholar
• Shiah IS, Yatham LN, Lam RW, Zis AP. Effects of lamotrigine on the 5-HT1A receptor function in healthy human males. J Affect Disord 1998;49:157–62
   PubMed Web of Science ®Google Scholar
• Giorgi L, Gomez G, O’Neill F, Hammer AE, Risner M. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001;18:621–30
   PubMed Web of Science ®Google Scholar
• Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312–22
   PubMed Web of Science ®Google Scholar
• Maltese TM. Adjunctive lamotrigine treatment for major depression. Am J Psychiatry 1999;156:1833
   PubMed Web of Science ®Google Scholar
• Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001;10:661–71
   PubMed Web of Science ®Google Scholar
• De Leon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry 2001;9:209–22
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Rapport DJ, Kimmel SE, Shelton MD. Controlled trials in bipolar I depression: focus on switch rates and efficacy [Review]. Eur Neuropsychopharmacol 1999;9(Suppl 4):S109–12
   PubMedGoogle Scholar
• Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 2002;69:1–14
   Google Scholar
• Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4: 137–44
   PubMed Web of Science ®Google Scholar
• Chang KD, Ketter TA. Special issues in the treatment of paediatric bipolar disorder. Expert Opin Pharmacother 2001;2:613–622
   PubMedGoogle Scholar
• Erfurth A, Walden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 1998;38:204–5
   Google Scholar
• Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997;73:223–30
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57:505–9
   PubMed Web of Science ®Google Scholar
• Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001;21(9 I):1070–81
   PubMed Web of Science ®Google Scholar
• Chatham Showalter PE, Kimmel DN. Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine. Brain Injury 2001;14:997–1001
   Web of Science ®Google Scholar
• Lizasoain I, Leza JC. Cuellar B, Moro MA, Lorenzo P. Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide. Eur J Pharmacol 1996;299:41–5
   PubMed Web of Science ®Google Scholar
• Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997;17:185–9
   PubMed Web of Science ®Google Scholar
• Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997;72:145–8
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL. Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60: 79–88
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607–14
   PubMed Web of Science ®Google Scholar
• Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253–60
   PubMed Web of Science ®Google Scholar
• Walden J, Schaerer L, Schloesser S, Grunze H. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord 2000;2:336–9
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522–7
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61:841–50
   PubMed Web of Science ®Google Scholar
• Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51:333–43
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE Jr, Rhodes L, Bolden-Watson C, Zhou J, Ascher JA. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019–23
   PubMed Web of Science ®Google Scholar
• Yalcin B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. J Am Acad Dermatol 2000;43(5 Pt 2):898–9
   PubMedGoogle Scholar
• Besag FMC, Ng GYT, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000;9:282–6
   PubMed Web of Science ®Google Scholar
• Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2003;4:21–30
   PubMed Web of Science ®Google Scholar
• Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, Risner ME. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995;8:201–9
   Google Scholar
• Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38:881–6
   PubMed Web of Science ®Google Scholar
• Maggs JL, Naisbitt DJ, Tettey JNA, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075–81
   PubMed Web of Science ®Google Scholar
• Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13:89–92
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Perrine KR, Vazquez BR, Kiolbasa T. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001;56:1177–82
   PubMed Web of Science ®Google Scholar
• Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172–7
   PubMed Web of Science ®Google Scholar
• O’Donnell J, Bateman DN. Lamotrigine overdose in an adult. J Toxicol Clin Toxicol 2000;38:659–660
   PubMed Web of Science ®Google Scholar
• Wong ICK, Mawer GE, Sander JWAS. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001;42:237–44
   PubMed Web of Science ®Google Scholar
• Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants [Review]. Cell Mol Neurobiol 1999;19:511–32
   PubMed Web of Science ®Google Scholar
• Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P. Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 2000;38:540–5
   PubMed Web of Science ®Google Scholar
• Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433–43
   PubMed Web of Science ®Google Scholar
• Mustafa AA, Al-Humayyd MS. The effect of parenteral imipramine on the oral absorption of lamotrigine in rats. Int J Pharm 1997;152:207–13
   Google Scholar
• Chen C, Veronese L, Yin Y, The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000;50:193–5
   PubMed Web of Science ®Google Scholar
• Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review [Review]. J Clin Psychiatry 2000;61:79–90
   PubMed Web of Science ®Google Scholar
• Rambeck B, Kurlemann G, Stodieck SRG, May TW, Jurgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 1997;51:481–4
   PubMed Web of Science ®Google Scholar
• Tennis P, Eldridge RR; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002;43:1161–7
   PubMed Web of Science ®Google Scholar